Vmbook Online ordering

Intermune Inc

**Intermune Inc.**

**Company Overview**

* **Industry:** Biotechnology

* **Headquarters:** Brisbane, California, USA

* **Founded:** 1998

* **Ticker Symbol:** ITMN (NASDAQ)

**Business Description**

Intermune Inc. was a publicly traded biotechnology company that focused on developing and commercializing innovative therapies for serious diseases. Its primary focus was on the development of treatments for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.

**Products and Pipeline**

Intermune's main product was Esbriet (pirfenidone), a drug approved for the treatment of IPF. The company also had a pipeline of investigational drugs for other fibrotic diseases, including:

* Actimis (budesonide/formoterol)

* INM-001 (a monoclonal antibody)

* INM-002 (a kinase inhibitor)

**Financial Performance**

In 2014, Intermune reported:

* Revenue: $1.1 billion

* Net income: $238.9 million

* Earnings per share: $2.36

**Acquisition**

In 2014, Intermune was acquired by Roche Holding AG for approximately $8.3 billion. The acquisition strengthened Roche's position in the respiratory disease market and provided access to Intermune's IPF treatment portfolio.

**Delisting**

Following the acquisition, Intermune Inc. was delisted from the NASDAQ stock exchange on March 13, 2015. Its shares are no longer publicly traded.